24.1 Research Ethics, IRB Oversight & Protection of Human Subjects

Why This Topic Matters on the NCE

Domain III.A of the content outline has exactly two sub-topics: autonomy, beneficence, and nonmaleficence — and research ethics. The NBCRNA moved professional issues onto the NCE deliberately. CRNAs participate in clinical trials, quality improvement, and Doctor of Nursing Practice scholarly projects, and the questions test whether you know when consent is required, who approves the work, and what protections apply to vulnerable subjects.

---

1. How Modern Research Ethics Was Built

---

2. The Belmont Report: Three Principles

The Belmont mapping is a classic exam item: each principle pairs with one specific application. Justice is the principle violated when a study recruits only from a poor, institutionalized, or captive population because they are convenient.

---

3. The Institutional Review Board

An IRB reviews research to approve, require modification of, or disapprove it, and conducts continuing review.

• Membership requires at least five members, including at least one scientist, at least one nonscientist, and at least one member not affiliated with the institution.
• Review categories: exempt (minimal risk, defined categories such as certain educational or de-identified data research), expedited (minimal risk, defined categories, reviewed by the chair or a designee), and full board (everything else, including more-than-minimal-risk research).
• The 2018 revised Common Rule, effective January 21, 2019, requires a concise key-information summary at the beginning of the consent form, mandates a single IRB of record for most federally funded multisite research, and permits broad consent for secondary use of identifiable data and biospecimens.

Vulnerable populations receive additional federal protection

• Subpart B — pregnant women, human fetuses, and neonates
• Subpart C — prisoners
• Subpart D — children (assent from the child plus permission from parents or guardians)
• Decisionally impaired adults require a legally authorized representative

---

4. Informed Consent for Research

Consent for research is not the same as clinical consent. The required elements include:

1. A statement that the study involves research, and its purpose and expected duration
2. Description of the procedures, and identification of which are experimental
3. Reasonably foreseeable risks and discomforts
4. Reasonably expected benefits — and where there are none to the subject, that must be stated
5. Disclosure of appropriate alternative procedures or treatments
6. Extent of confidentiality of records
7. Compensation and treatment available for research-related injury in more-than-minimal-risk research
8. Whom to contact for questions about the research, subjects' rights, and injury
9. A statement that participation is voluntary, that refusal involves no penalty or loss of benefits, and that the subject may withdraw at any time

Therapeutic misconception — the subject's belief that a trial is individualized treatment rather than research — is the most common failure of research consent, and the consent process must actively correct it.

Waivers and exceptions

• Waiver of consent is possible only for minimal-risk research that could not practicably be carried out otherwise and that does not adversely affect subjects' rights and welfare.
• Exception from informed consent (EFIC) under 21 CFR 50.24 allows emergency research in life-threatening situations where consent is impossible, but requires community consultation and public disclosure before and after the study.

---

5. Scientific Integrity in Trial Design and Conduct

• Clinical equipoise — genuine uncertainty within the expert community about which arm is superior — is the ethical justification for randomization. If a treatment is known to be better, randomizing patients away from it is unethical.
• Placebo controls are ethical when there is no proven effective therapy, or when withholding it causes only temporary discomfort without serious harm. Placebo is not acceptable when an effective therapy exists and withholding it risks serious harm.
• A Data and Safety Monitoring Board conducts interim analyses and can stop a trial early for harm, for overwhelming benefit, or for futility.
• Research misconduct is federally defined as fabrication, falsification, or plagiarism. Honest error and differences of scientific opinion are not misconduct.
• Conflicts of interest — financial relationships with sponsors, device manufacturers, and drug companies — must be disclosed to the IRB, to subjects, and in publication.
• Authorship requires substantial contribution; gift and ghost authorship are unethical.
• Clinical trial registration on ClinicalTrials.gov before enrollment is required by the International Committee of Medical Journal Editors for publication.

---

6. Research Versus Quality Improvement

This distinction matters practically because it determines whether IRB review is required.

HIPAA applies to both: protected health information used in research requires either authorization, a waiver of authorization from the IRB or privacy board, a limited data set with a data use agreement, or full de-identification.

---

Exam Traps

• Belmont principles map one-to-one to applications: respect for persons to informed consent, beneficence to risk-benefit analysis, justice to equitable subject selection.
• Research misconduct is fabrication, falsification, and plagiarism — not honest error.
• Equipoise is required to randomize.
• Children give assent; parents give permission. Neither is called consent.
• The IRB must include a nonscientist and an unaffiliated member.